BTG2 suppresses the growth and metastasis of cervical squamous cell carcinoma.

[1]  Yonghua Wang,et al.  BTG2 and SerpinB5, a novel gene pair to evaluate the prognosis of lung adenocarcinoma , 2023, Frontiers in Immunology.

[2]  Congcong Cao,et al.  BTG2 suppresses renal cell carcinoma progression through N6-methyladenosine , 2022, Frontiers in Oncology.

[3]  J. Brower,et al.  Management of radiographically positive pelvic and/or paraaortic lymph nodes during primary chemoradiotherapy for cervix cancer. , 2022, Practical radiation oncology.

[4]  Inuk Jung,et al.  Emerging role of antiproliferative protein BTG1 and BTG2 , 2022, BMB reports.

[5]  Saijun Fan,et al.  Elevated BTG2 improves the radiosensitivity of non‐small cell lung cancer (NSCLC) through apoptosis , 2022, Thoracic cancer.

[6]  Ping Fan,et al.  BTG2 Serves as a Potential Prognostic Marker and Correlates with Immune Infiltration in Lung Adenocarcinoma , 2022, International journal of general medicine.

[7]  P. Mokarram,et al.  Expression and methylation status of BTG2, PPP1CA, and PEG3 genes in colon adenocarcinoma cell lines: promising treatment targets , 2022, Gastroenterology and hepatology from bed to bench.

[8]  A. Lánczky,et al.  Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation , 2021, Journal of medical Internet research.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  X. Bian,et al.  Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinoma. , 2020, The Journal of clinical investigation.

[11]  R. Flavell,et al.  mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence , 2020, Science.

[12]  Probal Banerjee,et al.  Dietary Polyphenols, Resveratrol and Pterostilbene Exhibit Antitumor Activity on an HPV E6-Positive Cervical Cancer Model: An in vitro and in vivo Analysis , 2019, Front. Oncol..

[13]  B. Scheijen,et al.  Tumor suppressors BTG1 and BTG2: Beyond growth control , 2018, Journal of cellular physiology.

[14]  J. Hanprasertpong,et al.  Preoperative Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Not Clinically Useful in Predicting Prognosis in Early Stage Cervical Cancer , 2018, Surgery research and practice.

[15]  M. Phipps,et al.  Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[16]  D. Noh,et al.  TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis , 2018, Journal of Cancer Research and Clinical Oncology.

[17]  C. Bassing,et al.  Flip the switch: BTG2–PRMT1 protein complexes antagonize pre-B-cell proliferation to promote B-cell development , 2018, Cellular & Molecular Immunology.

[18]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[19]  Lili Kang,et al.  RABEX-5 overexpression in gastric cancer is correlated with elevated MMP-9 level. , 2016, American journal of translational research.

[20]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[21]  A. Dueñas-González,et al.  New molecular targets against cervical cancer , 2014, International journal of women's health.

[22]  James Lee,et al.  Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells , 2013, Journal of Cell Science.

[23]  M. Markman.  Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions , 2013, Oncology.

[24]  F. Hoppe-Seyler,et al.  Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients , 2013, British Journal of Cancer.

[25]  Jinming Yu,et al.  BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo. , 2012, Oncology research.

[26]  Jeong-Won Lee,et al.  A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. , 2011, Gynecologic oncology.

[27]  M. Rath,et al.  In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. , 2010, Oncology reports.

[28]  Motoki Abe,et al.  Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. , 2008, The Journal of surgical research.

[29]  M. Sherman,et al.  Mortality trends for cervical squamous and adenocarcinoma in the United States , 2005, Cancer.

[30]  B. Monk,et al.  New developments in the treatment of invasive cervical cancer. , 2002, Obstetrics and gynecology clinics of North America.

[31]  Paola Pisani,et al.  Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population , 2002, International journal of cancer.

[32]  J. Inazawa,et al.  ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system , 1998, Oncogene.

[33]  C. Brinckerhoff,et al.  The AP-1 site and MMP gene regulation: what is all the fuss about? , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[34]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.